Q-omics provides the consensus-scored PRDM8 profile across patient tissues and cancer cell-line models. PRDM8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PRDM8 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PRDM8 RNA expression shows 22,564 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, BLCA, and LSCC as cancer lineages where PRDM8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRDM8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRDM8 survival associations across molecular data types. PRDM8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRDM8 RNA expression–survival associations across cancer types. High PRDM8 expression shows unfavorable associations in KIRP, UVM, MESO and LUAD, but favorable associations in SKCM and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PRDM8 RNA expression.
This table summarizes PRDM8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRDM8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRDM8 shows lower tumor expression in BLCA, UCEC, BRCA and THCA and higher tumor expression in LUAD and HNSC. The BLCA box plot shows higher PRDM8 RNA expression in normal versus tumor tissue (log2 FC = −2.072, t-test p = .001).
This table shows molecular features associated with PRDM8 in patient tissues and cancer cell lines. In patient samples, PRDM8 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRDM8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
